Steg PG, et al. - Researchers investigated death following index acute coronary syndrome in relation to treatment with alirocumab via this analysis of ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab), a double-blind, randomized clinical trial comparing alirocumab to placebo. Participants were 18,924 patients who had an acute coronary syndrome 1 to 12 months previously and elevated atherogenic lipoproteins even with intensive statin treatment who were followed-up for a median of 2.8 years. In the alirocumab and placebo groups, death was reported in 334 (3.5%) and 392 (4.1%) patients, respectively. Findings revealed the possible benefit of alirocumab added to intensive statin therapy with regard to reducing death post-acute coronary syndrome, especially if treated for ≥3 years, if baseline low-density lipoprotein cholesterol (LDL-C) is ≥100 mg/dL, or if achieved LDL-C is low.